New Medication for Early-Stage Non-small cell Lung Cancer

Trial Objective

Researchers are testing a medication called atezolizumab and its effects on early-stage non-small cell lung cancer (NSCLC). Atezolizumab is an experimental immunotherapy medicine, which is a man-made antibody.

Antibodies are used by the immune system to identify and destroy bacteria, viruses and tumor cells. Atezolizumab is approved to treat advanced cancer of the bladder and lung, and researchers believe it may help people who have early-stage NSCLC. In this study, participants will get either atezolizumab and chemotherapy or a placebo and chemotherapy before undergoing surgery to remove their tumor.

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Jami Henriksen at 303.398.1233 or complete the form below.

Who Can Participate

Adults diagnosed with early-stage non-small cell lung cancer (NSCLC) that can be surgically removed.

Estimated Time Commitment

The screening period may last up to 6 weeks and involve up to 2 visits to the clinic.

One group will receive pre-surgery treatment for up to 12 weeks, then undergo surgery, followed by taking atezolizumab for up to 48 weeks. The other group will receive pre-surgery treatment for up to 12 weeks, undergo surgery and then be given the best supportive care and monitoring. Maximum of clinic visits would be once a week.